HOOKIPA Pharma Inc. (HOOK)

NASDAQ: HOOK · IEX Real-Time Price · USD
0.712
-0.008 (-1.17%)
At close: Mar 28, 2024, 4:00 PM
0.730
+0.018 (2.53%)
After-hours: Mar 28, 2024, 7:59 PM EDT
-1.17%
Market Cap 71.28M
Revenue (ttm) 20.13M
Net Income (ttm) -81.58M
Shares Out 81.55M
EPS (ttm) -0.86
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 375,761
Open 0.726
Previous Close 0.720
Day's Range 0.710 - 0.740
52-Week Range 0.410 - 2.050
Beta 1.03
Analysts Strong Buy
Price Target 4.44 (+523.6%)
Earnings Date Mar 22, 2024

About HOOK

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 18, 2019
Employees 151
Stock Exchange NASDAQ
Ticker Symbol HOOK
Full Company Profile

Financial Performance

In 2023, HOOKIPA Pharma's revenue was $20.13 million, an increase of 41.27% compared to the previous year's $14.25 million. Losses were -$81.58 million, 25.7% more than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for HOOK stock is "Strong Buy." The 12-month stock price forecast is $4.44, which is an increase of 523.60% from the latest price.

Price Target
$4.44
(523.60% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

NEW YORK and VIENNA, Austria, March 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavir...

6 days ago - GlobeNewsWire

HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference

NEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavir...

22 days ago - GlobeNewsWire

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

NEW YORK and VIENNA, Austria, Jan. 29, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

2 months ago - GlobeNewsWire

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

NEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

2 months ago - GlobeNewsWire

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

NEW YORK and VIENNA, Austria, Dec. 21, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

3 months ago - GlobeNewsWire

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

NEW YORK and VIENNA, Austria, Nov. 20, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

4 months ago - GlobeNewsWire

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

NEW YORK and VIENNA, Austria, Nov. 09, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

5 months ago - GlobeNewsWire

HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023

NEW YORK and VIENNA, Austria, Nov. 03, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

5 months ago - GlobeNewsWire

HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023

NEW YORK and VIENNA, Austria, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

5 months ago - GlobeNewsWire

HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023

NEW YORK and VIENNA, Austria, Oct. 22, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

5 months ago - GlobeNewsWire

HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences

NEW YORK and VIENNA, Austria, Oct. 18, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

5 months ago - GlobeNewsWire

HOOKIPA Announces Executive Leadership Change

NEW YORK and VIENNA, Sept. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platfo...

7 months ago - GlobeNewsWire

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and VIENNA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platfo...

7 months ago - GlobeNewsWire

HOOKIPA Pharma to participate in upcoming investor conferences in September

NEW YORK and VIENNA, Austria, Sept. 06, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavir...

7 months ago - GlobeNewsWire

HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

NEW YORK and VIENNA, Austria, Aug. 10, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

8 months ago - GlobeNewsWire

HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023

NEW YORK and VIENNA, Austria, Aug. 03, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

8 months ago - GlobeNewsWire

HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and VIENNA, Austria, June 10, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

10 months ago - GlobeNewsWire

HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock

NEW YORK and VIENNA, Austria, May 31, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...

10 months ago - GlobeNewsWire

HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers

NEW YORK and VIENNA, Austria, May 31, 2023 (GLOBE NEWSWIRE) --  HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenaviru...

10 months ago - GlobeNewsWire

HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

NEW YORK and VIENNA, May 11, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform...

11 months ago - GlobeNewsWire

HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B

NEW YORK and VIENNA, Austria, May 09, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...

11 months ago - GlobeNewsWire

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May

NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...

11 months ago - GlobeNewsWire

HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023

NEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...

11 months ago - GlobeNewsWire

HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO

NEW YORK and VIENNA, Austria, April 26, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavir...

1 year ago - GlobeNewsWire

HOOKIPA Pharma to Participate in the Van Lanschot Kempen Life Sciences Conference

NEW YORK and VIENNA, Austria, April 19, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA'), a company developing a new class of immunotherapeutics based on its proprietary arenavir...

1 year ago - GlobeNewsWire